<SEC-DOCUMENT>0001023024-24-000088.txt : 20240916
<SEC-HEADER>0001023024-24-000088.hdr.sgml : 20240916
<ACCEPTANCE-DATETIME>20240916091356
ACCESSION NUMBER:		0001023024-24-000088
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240916
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240916
DATE AS OF CHANGE:		20240916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANI PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001023024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				582301143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31812
		FILM NUMBER:		241299498

	BUSINESS ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623
		BUSINESS PHONE:		2186343500

	MAIL ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOSANTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19991228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEN ABRAHAM TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19991027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ani-20240916.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:835caa92-ff5e-4b29-98d4-4fc6bee3758f,g:0db09cdd-95a2-4125-b62d-a2bb22005884,d:07cb2d179bc24dc897b335ae128fc685-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ani-20240916</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001023024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ani-20240916.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-16</xbrli:startDate><xbrli:endDate>2024-09-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i07cb2d179bc24dc897b335ae128fc685_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">September 16, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ANI PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-31812</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">58-2301143</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">210 Main Street West</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Baudette</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Minnesota</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">56623</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">218</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">634-3500</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">ANIP</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-16">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-17">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-18">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-19">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Growth Company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#168;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07cb2d179bc24dc897b335ae128fc685_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Events</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2024, ANI Pharmaceuticals, Inc., issued a press release announcing the completion of the previously announced acquisition of Alimera Sciences, Inc., pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.</span></div><div id="i07cb2d179bc24dc897b335ae128fc685_10"></div><div style="-sec-extract:summary;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anipclosing-20240916xexx991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anipclosing-20240916xexx991.htm">Press Release of the Company, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anipclosing-20240916xexx991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anipclosing-20240916xexx991.htm">September 16</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anipclosing-20240916xexx991.htm">, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded with the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07cb2d179bc24dc897b335ae128fc685_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: September 16, 2024</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Stephen P. Carey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stephen P. Carey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President Finance and Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>anipclosing-20240916xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iedb1bbf23b5947db8ef2f64ab32d915a_35"></div><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><img alt="imagea.jpg" src="imagea.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:185px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR IMMEDIATE RELEASE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:110%">ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Adds two durable commercial assets ILUVIEN&#174; and YUTIQ&#174; with significant growth potential, expanding ANI&#8217;s foothold in strategic therapeutic area of ophthalmology</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Anticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafter</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">New capital structure in place, reducing interest expense by approximately $39 million on an annualized basis </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin&#174; Gel (Cortrophin Gel) and Generics</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">PRINCETON, N.J., September 16, 2024 (GLOBE NEWSWIRE)&#8212;ANI Pharmaceuticals, Inc. (&#8220;ANI&#8221; or &#8220;the Company&#8221;) (Nasdaq&#58; ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq&#58; ALIM) (&#8220;Alimera&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Nikhil Lalwani, President and CEO of ANI, stated, &#8220;Today marks a major milestone in our strategy to expand our Rare Disease business and deliver on our purpose of &#8216;Serving Patients, Improving Lives.&#8217; Alimera is highly synergistic to our Rare Disease business, and we believe our proven commercial execution capabilities can further unlock the value of ILUVIEN and YUTIQ, two growing and durable assets, as well as accelerate the growth of Cortrophin Gel in ophthalmology. We continue to expect the transaction to create substantial shareholder value and generate high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS with substantially higher accretion thereafter.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;With this acquisition, ANI now has three commercial rare disease assets, an expanded global footprint, and a robust Rare Disease team covering the specialties of ophthalmology, neurology, nephrology, rheumatology, and pulmonology. I want to thank the employees of both companies and our advisors for their cooperation and diligence in closing this transformational transaction. We are thrilled to welcome Alimera to the ANI team,&#8221; concluded Lalwani.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Stephen Carey, Senior Vice President and Chief Financial Officer of ANI said, &#8220;ANI&#8217;s new capital structure provides us significant financial flexibility to support the integration of Alimera and continue investing in organic growth initiatives while also significantly reducing our interest expense and increasing cash flow.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As compared to estimated interest expense that would have been incurred if the new principal amount of debt was subject to rates that would have applied under the previous debt capital structure</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Transaction Rationale</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Solidifies Rare Disease segment as the largest driver of future growth&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> The combination with Alimera creates an attractive Rare Disease growth platform, adding approximately $105 million in 2024 revenue on a pro forma basis and expanding the Rare Disease segment to approximately 45% of pro forma 2024 revenues. The transaction also expands ANI&#8217;s footprint beyond the U.S. to 20 countries in Europe and beyond. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Adds two durable commercial products with significant growth potential that leverage the Company&#8217;s existing Rare Disease infrastructure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#58; ILUVIEN and YUTIQ are durable assets with high barriers to genericization which the Company believes have a clear role for patients in need of alternative therapeutic options. ANI sees the potential to unlock significant additional growth for both ILUVIEN and YUTIQ through commercial synergies and execution.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Expands foothold in ophthalmology and expected to accelerate growth of Cortrophin Gel in this key therapeutic area&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> During the first quarter of 2024, ANI launched a targeted ophthalmology-focused sales force for Cortrophin Gel. The team has continued to gain momentum in ophthalmology, driving significant growth in the number of new patient starts in the second quarter and third quarter to date. Importantly, the addition of Alimera expands the reach of the ophthalmology sales team to over 3,600 physicians. The Company estimates that there is over 50% overlap between high potential prescribers of Cortrophin Gel, ILUVIEN and YUTIQ.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Offers potential for substantial shareholder value creation&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">ANI continues to expect high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS with substantial accretion thereafter. The transaction is anticipated to deliver an additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Business Updates</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Cortrophin Gel&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">ANI continues to see momentum across all targeted specialties and prescription growth across both existing and new prescribers. In August, the Cortrophin Gel franchise experienced a record number of new patients starts and the Company believes there is significant room for future growth as the number of patients on ACTH therapy remains significantly lower it was than a few years ago.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Generics&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Strong R&#38;D capabilities enabled ANI to launch four products in the third quarter to date, bringing the number of products launched year-to-date to fourteen. In addition, the Company&#8217;s operational excellence leveraging its U.S. based manufacturing footprint and a robust FDA compliance track record continues to enable ANI to deliver high-single-digit to low double-digit growth in Generics.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Alimera Integration&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">ANI has made substantial progress on integration planning and expects the combined ophthalmology commercial team to begin generating synergies across Cortrophin Gel, ILUVIEN and YUTIQ in the near-term. The Company will leverage its manufacturing, quality, and regulatory expertise to further strengthen supply-security for ILUVIEN and YUTIQ.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:13.8pt">Guidance&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">ANI is maintaining its 2024 guidance for the standalone Company based on continued momentum across Cortrophin Gel and Generics and plans to provide 2024 guidance for the combined Company by no later than the Company&#8217;s third quarter earnings call. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Terms of the Transaction</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:13.8pt">Under the terms of the merger agreement, ANI acquired all of the outstanding shares of Alimera for $5.50 per share. The Company also repaid $72.5 million of Alimera debt. Alimera investors received one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">New Capital Structure</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">ANI recently completed an offering of $316.25 million aggregate principal amount of 2.25% convertible senior notes due September 1, 2029. The Company utilized a majority of the net proceeds as well as cash from its balance sheet to repay in full its existing senior secured term loan facility ($292.5 million that carried an interest rate of SOFR+6.0%). The initial conversion price of the convertible notes is $74.11 per share. Concurrent with the convertible offering, the Company used $40.6 million of the net proceeds to enter into capped call transactions. The cap price of the capped call transactions is initially $114.02 per share, which represents a premium of 100% over the last reported sale price of the Company&#8217;s common stock on August 7, 2024. The capped call transactions are expected generally to reduce the potential dilution to ANI&#8217;s common stock upon any conversion of the notes up to the cap price of $114.02.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:13.8pt">To fund the acquisition of Alimera, ANI entered into a new senior secured credit agreement consisting of a $325 million delayed draw term loan facility and $75 million revolving credit facility (initial interest rate SOFR+2.75%). On September 16, 2024 the Company drew the full $325 million term loan&#59; the $75 million revolving credit facility remains un-drawn.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:13.8pt">The Company expects these capital structure changes to reduce interest expense by approximately $39 million on an annualized basis as compared to estimated interest expense that would have been incurred if the new principal amount of debt was subject to rates that would have applied under the previous debt capital structure.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Advisors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Guggenheim Securities, LLC acted as lead financial advisor to ANI and Raymond James &#38; Associates, Inc. also acted as financial advisor. Hughes Hubbard &#38; Reed LLP acted as legal advisor to ANI. Centerview Partners LLC acted as lead financial advisor to Alimera, and Perella Weinberg Partners also acted as a financial advisor to Alimera. DLA Piper acted as legal advisor to Alimera.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About ANI Pharmaceuticals, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">ANI Pharmaceuticals, Inc. (Nasdaq&#58; ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. ANI is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin&#174; Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This press release contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company&#8217;s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;shall,&#8221; &#8220;would&#8221; other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements&#58; (i) the ability to implement business plans, forecasts, and other expectations in connection with the acquisition and integration of Alimera Sciences, and identify and realize additional opportunities and, in particular, the possibility that the Company is unable to achieve anticipated synergies, (ii) costs and regulatory requirements relating to contract manufacturing arrangements, (iii) costs or delays associated with manufacturing (including the sources and any changes in sources thereof) of the Company&#8217;s products, (iv) delays or failures in retaining and obtaining continuing and future product approvals from the FDA, and other regulatory issues relating to the Company's business and products, (v) market trends for the Company&#8217;s products, including but not limited to, ILUVIEN, YUTIQ and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Cortrophin Gel, and the ability to achieve anticipated sales for such products, (vi) risks that the acquisition of Alimera may disrupt current plans and operations of the Company and potential difficulties of the Company in retaining employees of Alimera and&#47;or maintaining business relationships of Alimera, (vii) the impact of any litigation to which the Company is, or may become, a party, including in connection with the acquisition and integration thereof, (viii) volatility in the Company&#8217;s stock price, including as a result of the acquisition, (ix) changes in competitive and </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">regulated industries in which the Company operates, variations in operating performance across competitors, changes in laws and regulations affecting the Company&#8217;s business, and changes in the Company&#8217;s capital structure as a result of the acquisition, (x) regulatory and other approvals relating to product development and manufacturing, (xi) the Company&#8217;s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries and&#47;or the Company and its products, (xii) costs incurred in connection with the acquisition of Alimera and the possibility that the Company is unable to realize anticipated benefits of the acquisition or to realize estimated pro forma results and underlying assumptions, (xiii) delays in production, increased costs and potential loss of revenues if there is a change in manufacturers or manufacturing processes due to the limited number of suppliers for the Company&#8217;s raw materials, active pharmaceutical ingredients, excipients and other materials, (xiv) the Company&#8217;s reliance on single source third-party contract manufacturing supply for certain of its key products, including ILUVIEN, YUTIQ and Cortrophin Gel, (xv) changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration, and other regulatory agencies, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions, (xvi) the impact of legislative or regulatory reform on the pricing for the Company&#8217;s products, (xvii) the Company&#8217; ability to maintain the services of its key executives and other personnel, and (xviii) general business and economic conditions, such as inflationary pressures, geopolitical conditions including, but not limited to, the conflict between Russia and the Ukraine, the conflict between Israel and Gaza, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This press release refers to financial measures that are not in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. A reconciliation of the forward-looking non-GAAP measures presented in this communication is not provided due to the inherent difficulty in forecasting and quantifying items that are necessary for such reconciliation. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on future financial performance. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">More detailed information on these and additional factors that could affect the Company&#8217;s actual results are described in the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company&#8217;s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Investor Relations&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Lisa M. Wilson, In-Site Communications, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">T&#58; 212-452-2793</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">E&#58; lwilson&#64;insitecony.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ani-20240916.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:835caa92-ff5e-4b29-98d4-4fc6bee3758f,g:0db09cdd-95a2-4125-b62d-a2bb22005884-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ani="http://ani.com/20240916" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ani.com/20240916">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ani-20240916_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ani-20240916_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://ani.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ani-20240916_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:835caa92-ff5e-4b29-98d4-4fc6bee3758f,g:0db09cdd-95a2-4125-b62d-a2bb22005884-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_d4830ec8-e5e1-460b-9e88-7b680a8598d3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_189a4113-9f0a-434a-b209-fa7fd443b480_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_90994d00-95da-4d14-930f-0de0c323f740_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_23f0216b-3166-4d90-9a0d-47f806e4e121_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e5df7506-f80c-47da-870a-f141f490aeaf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_285394f8-02fa-4c43-a6b2-92d61b1b12b8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_33f95684-f24d-4d75-9f04-8fb6cb6d6703_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3654dee9-d23f-476d-91ec-97e474505975_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2efabe12-7112-485f-9d14-e451c6451c80_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_269271ec-9102-4a70-8e18-27e456a1a3e5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_92296a7e-652b-41af-ba1a-d44d02985c2d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2cafc5f6-50b0-4341-ad3b-c675c7a4a3a0_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7e45f416-6c04-40c1-9adb-cd2f342b7ad1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_aa3bfd05-4a1f-4666-8b6a-279c6b3dd681_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f79f96e3-73d8-4ecc-902a-095c5a95ff4d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7b1cab5a-29d8-487b-91bf-e7d999621936_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3905a914-f4a1-411f-87db-925c877c0512_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3649f731-9b90-4e90-a5ae-3d00dad995c3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_51467e43-6f66-4fbd-af0d-56fc7cd1e807_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_be8bfc4a-6107-4102-86e7-3fc6cb305cb1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6cc9b4d4-013d-45a4-93f5-5fc205fae3d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4c3d2883-9910-4b3c-b15a-55da857e376e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ani-20240916_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:835caa92-ff5e-4b29-98d4-4fc6bee3758f,g:0db09cdd-95a2-4125-b62d-a2bb22005884-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ani.com/role/Cover" xlink:type="simple" xlink:href="ani-20240916.xsd#Cover"/>
  <link:presentationLink xlink:role="http://ani.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_52fa5793-96e9-421d-b122-04d3aec16732" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_DocumentType_52fa5793-96e9-421d-b122-04d3aec16732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_911ed704-00a4-4358-9bdc-4ba9bbe405e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_DocumentPeriodEndDate_911ed704-00a4-4358-9bdc-4ba9bbe405e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_82c662fa-592d-4cea-a209-ac79df141c24" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityRegistrantName_82c662fa-592d-4cea-a209-ac79df141c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cc5ac519-7494-4934-8124-7824de8b0381" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cc5ac519-7494-4934-8124-7824de8b0381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f99fb233-45f5-4883-9943-c4ad820283eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityFileNumber_f99fb233-45f5-4883-9943-c4ad820283eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_213efd10-e7c1-4b42-9ef5-d4d328c506cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityTaxIdentificationNumber_213efd10-e7c1-4b42-9ef5-d4d328c506cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_250fb9ee-83c8-4172-8ca9-051d58cd2f4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityAddressAddressLine1_250fb9ee-83c8-4172-8ca9-051d58cd2f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_943a4e88-e717-44f8-9911-a8c5f7a222f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityAddressCityOrTown_943a4e88-e717-44f8-9911-a8c5f7a222f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c8a3f2f4-8d58-41d1-97d6-a6ae6bf0eedd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityAddressStateOrProvince_c8a3f2f4-8d58-41d1-97d6-a6ae6bf0eedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e49a38c3-0cab-4fb1-b017-4a7d22855057" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityAddressPostalZipCode_e49a38c3-0cab-4fb1-b017-4a7d22855057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b04d6abf-d670-427f-a1fa-588bf7c6d6e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_CityAreaCode_b04d6abf-d670-427f-a1fa-588bf7c6d6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0325e037-2d4b-4f55-ace1-ec4cc924731d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_LocalPhoneNumber_0325e037-2d4b-4f55-ace1-ec4cc924731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_196ccd19-f92d-41aa-a991-010d4d8fc8f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_Security12bTitle_196ccd19-f92d-41aa-a991-010d4d8fc8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_45817b86-6431-44df-96d8-ecaa39b33fb9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_TradingSymbol_45817b86-6431-44df-96d8-ecaa39b33fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3eec6837-00d0-44c8-ac52-14f4c50e759c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_SecurityExchangeName_3eec6837-00d0-44c8-ac52-14f4c50e759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cdba4467-c365-4bcf-a4b5-bd34d9a10a01" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_WrittenCommunications_cdba4467-c365-4bcf-a4b5-bd34d9a10a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_762d6b5a-9e43-4c35-8b5b-64e4f4e07841" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_SolicitingMaterial_762d6b5a-9e43-4c35-8b5b-64e4f4e07841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_99bfb25a-9550-4ecc-9b98-467fff9a87a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_PreCommencementTenderOffer_99bfb25a-9550-4ecc-9b98-467fff9a87a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d6115ea9-a4a2-485b-bb08-0cfe896f42a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d6115ea9-a4a2-485b-bb08-0cfe896f42a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f3ad6765-7813-46a3-b7ff-2ca593bceeec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityEmergingGrowthCompany_f3ad6765-7813-46a3-b7ff-2ca593bceeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_193cdda3-8407-4015-971d-5a5414949d2c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_EntityCentralIndexKey_193cdda3-8407-4015-971d-5a5414949d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2b5d7b7e-3c20-4eb3-90b6-40328d7159ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea13b219-0e2c-4a21-8a02-4c024803545c" xlink:to="loc_dei_AmendmentFlag_2b5d7b7e-3c20-4eb3-90b6-40328d7159ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
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M$T3<L<#G.TD302)1$N6_*MH1"/Y?*V%OW^#5FE4(JET#+].EQMO4*?#!)IN
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M7[_36+]'HL+F'7!=L1Y]YRQ'<\_YJ.8Z$V5'>J+8$#?D=IDL#C$9*1TFP6*
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MBFWHO'@36L];BT;>*U%KVA+\X;D(I058BTB:E6O$=&21="VM=/JD#FXPZ2^
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MF*]Z5>6B76@?@XZOUV_L1(WA/8GV=-J4<HVV&P_CW*.GN'OA+.9-FX(6[3K
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M<4NT_<58J09!@NLM'-S59C?NC.41"5K16D9KDP0$B0\?/F#_GCUH4JL&DNI
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M7Z'?VC41W+(E7%$'% DKERZ<1_OF39$R2Q985*XI@.4*$]<EVLYFK#H3R-7
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M#J3[.^$D/#P"JQ8O0IE2Q9'"-A?,&D@*3#NIY==&JK,>)#@U/7HF)D@ZR,V
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M7H_??XQCM^[CF/\]'+_[&"<?/\/II\]Q[FDP+@8&J4-7^?@ #G+>?O%*ZBC
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M*&JW8<,&%4W")6(=\3V"KMVZ(&_>/"A6M(CJF/7JUH:MK;500%MX"$4^L/^
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%1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm44865261726896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 16, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 16,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANI PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">58-2301143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 Main Street West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baudette<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">56623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">634-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANIP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001023024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;%!+ 0(4 Q0    ( +M),%E #,P6[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +M),%F97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ NTDP67ZVH? U!   9A   !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +M),%F?H!OPL0(  .(,
M   -              "  7D,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MNTDP69>*NQS     $P(   L              ( !50\  %]R96QS+RYR96QS
M4$L! A0#%     @ NTDP6:K$(A8S 0  (@(   \              ( !/A
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +M),%DD'INBK0   /@!   :
M              "  9X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( +M),%EED'F2&0$  ,\#   3              "  8,2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  ,T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ani-20240916.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ani.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ani-20240916.htm">ani-20240916.htm</File>
    <File>ani-20240916.xsd</File>
    <File>ani-20240916_lab.xml</File>
    <File>ani-20240916_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ani-20240916.htm": {
   "nsprefix": "ani",
   "nsuri": "http://ani.com/20240916",
   "dts": {
    "inline": {
     "local": [
      "ani-20240916.htm"
     ]
    },
    "schema": {
     "local": [
      "ani-20240916.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ani-20240916_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ani-20240916_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://ani.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ani-20240916.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ani-20240916.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001023024-24-000088-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001023024-24-000088-xbrl.zip
M4$L#!!0    ( +M),%DH0'TO:PX  %-M   0    86YI+3(P,C0P.3$V+FAT
M;>T=:7/B./;[_ HM4[N=5,7&-D? 2=AB:+J'[<Y10&]/[9<M80O0M+$]D@BP
MOW[?DVT"@2203C?DF"\3+.E)[SYT].D_IZ. 7#,A>12>O;--ZQUAH1?Y/!R<
MO:MW&JW6NW_6?CG]FV'\\5O[,WD?>>,1"Q5I"$85\\F$JR%10T:^1N(;OZ;D
M*J"J'XF1823#&E$\$WPP5,2QG&+6+6L5;J50\BBM.D:_7V)&L>=4C6K%+QK%
MOE?N,58X+E7Z1P/7\GM6U?-]HUJBCE&TG9+1*SN^09U>SW$LJU2I%(]\USKV
M>HYO'U=[GE/TO4KUN%<HE"BSG0K JY3TO$,%. />H73Y]"PW5"IV\_G)9&).
M>R(P(S'(.Y9=R/,PX"%#O'-I=Y_Q>7_=5S+/'$37>6B ,4XAZXB-_"[0%H*6
MBH8>R\W7H0R M30B@WVSC+P2-)1(7:J 7[C*DF%5C(*=P8&>W^Z9%IM[5"Y.
MN[[W?7,ZEF$YANW,<97+F$X*V81V_H_SSQUOR$;4N(7QNA%VM5K-3Y$[<] K
M^"QUQ5;=U0THR&N.A<:73JYV.F34KYV.F*($AQKLKS&_/LLUHE"![!K=60S+
M\))?9SG%IBJO9\W7?OGEEU/%5<!J-.0&2JQ5M<NG^>3;:3Z!W(O\6>W4Y]=$
MJEG SG(^EW% 9VX8A0SFYU,7.S*1_,E]GX7Z3VB_ /T1W$NFGZHVZY_E/ ,8
M&-(10F+<;88PW:P!BQ,T:(4^FWYBLQSA_EFN;SAVKF8!:4'88'6G^26H6TQ2
M!S7V494_!'20(PF#SW(@$6Z?3YEO]&F @I+.ZN1J'^J?.\V5"?/+& K69P(L
M")-K^(+\<J66!U@2T?QS%7#C+"?Y* Y0./2WH< 5+[+ G$H?^*.GNYDCG5)&
M8Z%_:;5S4ZSUTA'K[#O3=,U^<1]_]SD31"^)K56^1NO3,KUO#ZYEGY:AQT"=
MR,]^@>@+]1X,9@WQ,:RJ@4)UNVV^3/^.KEE+]CN;)+^$=T:D.57R"_*8!ZE-
M1!>IPQ^RE_]%ZMV,2<5]Q$-CR-"HN\52K$XFW%=#U[:LO^=TO]JIC"G(0T\@
MQY*_$R"KH*@8 #05Q:[MQ K&*]H+6-;<BP0LV_"B(*"Q9&[VQTFF<8FA,O2@
MDQ18+U(J&KFX,O!LBGLT,&C !Z&+Y$F;;Q9M6LG"%9!'^=G,:;,)3?G5[]6*
M6;76-UFFK;_G-3R1-:;T*B0X^J": 1+F+ <^8QG9=/G0D_C1&(GQ*ZSP)*8^
M>F77(C; R";(:\P?(*P%E-"H)U3P0%29R"5<ROK#>B+AXDPX61]$"2S B <S
M]UV7CT"=+]B$M*,1#=\=2? (X*X$[R<=)?\?<^TBS*)_3A)4CP&.9DZ*NNT@
MF;]<M+K-]Z33K7>;G67A6%C]OJRVTVQ\:;>ZK6:'U"_>D^8?C=_K%Q^;I'%Y
M?M[J=%J7%SM$P=H(A:]4#D%N5!22]V;#A#"L5*S>N>I]%9L/E^USLKEWR^+4
MQ-4G/@Q,6<7XM.K $DK\6*2*:Y'ZQZ]VV3K9(UYL)E&@$NWF19>TFU>7[>X>
M+W\]U:^^M#M?ZK#^[B4!_>Z"$A.[0"[;Q"X=^(=DCS1Z/0*7'TCW]R99L$US
MNU1O= DTV]5"\=GQ!4,;$O5)F\614.0@^]VD$-PPJ4CS&C//I)GYA^XC[,&5
MCIB:21RU'/7Z\,48 8@A#C-\.C-FC J#A?,@&/P!BQ4;]2!FM,M'.J.]RY[L
M =DWLZS;YB5M-N 2DT)U 2T9;0JY6OVB1:Y^K[?/ZXWFEVZK >G"$6E=-,R-
M2;0ODGC0G%)/:<Q1 ,4<8T(ED3'S,/+W"0\)5Y)X0PC@F3C<A//EYQ/B%AS3
M*13N#7%W!:JX2>!]5Y2=Q=%./,5(>E4/;U,T(>:.?.VVVMD*O4B @=3%FHX"
MF]:(QJ$2LT;D+QL\K#=A\JE8+*)KA'-CZ8I@C5E )U2P.Y57^:^3PA]XP* S
M^(",6B6L$-A&P:[8SANY;I&K2Z>MM%CB::%<IETY5RM5#*=@V7:Q<"_QGEJM
MP1SORKUHO221()$:0BCQYUAPZ7,/J0/^1I=-^*(>'_X(*=HA_HUH-.(2MQP(
M:A-)1.*E8=DRVV;'),U1'$0S8/.R&I"+R#Q<%?!-ZCG/*(@H/EPG>T)0CS<1
M >NO$&%N9O>PJ+.M%:[[OF!2IO_[#/#LS (?YVJ.;9%S"N%L1PG&%/D*V=8>
M!^U/2I(&_'DINM%D'OQ4<K7?Z-AG2JT$/T=;I)Q+LVB+?RFN(-+B>A-LPT"L
MFJN=\S!D,E+T?HZ\V@ CI?!5!"0,_L/C)-!-2WX6A!?ELO-S(XN?1+X[W$Y*
M#TQ<8P'"QF,:$#9EWECQ:\QGP0,Q^4.<[6X1!]X39/XCO>I>U<)NBBSO)%$L
M8/$P"AD)=:!T1("MP1AY0R!#H\ [G[GDQU2R-U/:@\VU%@UN'5:]I*<V.J'*
M;2T]W,+<?HY #J^02LL)ANWD:N5"T2B4+&N/:W6;D?DB4J0>QP'H',CSSV'X
M>@'=_RKYP0=PL1!V)U4\H3TN_*2)>00=ZF/E+APP"";1)Y. 2D6$KBZ;&Q7S
M<"$[0JX#YEQPQ0%B4IUD O"(QT*.L4RI(@(]=)IA.P>]0W0&>$BK[BGWI94I
MGR[#L*NF55H_9.LR9<4\+E:_)UE)Z8V)B0O.E\@HX#[))"MMU5*XTOB\_'87
MCU:A@#+J#8D'6B@WB$U>#WD$U8Z^,QOUHN!@H\!M(^*(9)*73+N+= -'2Q:;
M)N:>@%&<##E\T86V&_.Y34ZP?%3G3B*^?/'</$!+7=;,=GI:Y><!6B%7PX)@
MA.6'R/OVB KZ&S>VYD9J5A*K,F=%4>_B7NV*!:_ )&VO+\W4;B6[[;?K1FC5
MEDM&=@D-G_3I7XD^D7,JOK&[ZWG?E23_.9:*]V<[(F9CR  _#&QI'(LH%ASW
M57K1E/18$$TPQ,=&3 1(Q?A$^CQ 5\HE)-"*A3Z$S! I2SX:!XJ&+!K+8$8D
M55SV9WID.B#J ;(TW9[1#0M' L8 !]**<):U]2$RCB8X#NMY'+<Y)#F0C)&/
M+&2"!J05PMAQ$I_73<=,EGNX46A>V;_0_*[@V#'+QY4G":>K9=-RG)]8^]]J
MV^@K $;@\F>9AJ]@%T!^T6N.PW0_23YXAM\N)R<.*R=/NTF=VH#]V7E+R0-H
M+-)G*3MNCT%]BDXIU5Y4VX64&M)D<F ?D\:'-G$*E@D='UE4?-/6-VWM0+CB
M@6"%@W-P3^"C@H=5]?B5J.H-;<@H)<ZJGMI%:MC.@JIF(=&RHA9!N'3/-UU]
MT]5'ZNJ58.A5\7*9OCZ 0:*X[/=Q/^$AG:V\$IT%&AG> I$>]+-VT3=T%7HC
M#4[ZONGPFPX_C0ZWI!PSL94F5]\T^0Y-+C"C>.!MILEIWR?:CM]MI:$5^D@5
M1GHSXNFJ RSU&YD,F3[!>:LDP"6!)0))$9L!&8AHHH9(W!C+!%02G_5A"GV#
M(,E$K%)6/;B5AL!7NUHHD ,4R.,3G8UDG;F^>Q#CW0/<X$PXY/0,9PVL)38E
M0(MSH,BMFW$+8,W'[)#OEE/-C.H?$ZHW4JION5G^TZU6<I@I6WVR^'3M#]_.
MMQXT6,^&?ZW^/;J#)U_6*B)?*<L-0<U8P#Q\I"2,M D;2Z9[ :II\0^?MN"Z
M#)=<I4="Z[F"&4ZN'S=!X0D!-V@1[)I+& ?*2T,/<Q7J>7B] COC\Q8^%;Y,
MRG[^7?OQA0,ZWX]?U$IS1R*:"<[#@E*Z2T[V*MYZOE?V%Y]4B*-$,%W! HH'
M]U8>6;A9@I[;NAE">S(*QFIUR$/O,FS[.,3Q_'&(H;B)?P;,Z E&OQFT#S[$
MI<&$SB1B__:"Q*(X/ME9D\IWGS7YD>'_DYY_:RDV(A73LK\O$-\OI"YU"*DO
M-\LM8N4UB87^!!X2(+F%\LX.IUV&9/6>]!'1]X.'%"(9CXTUZ>41:86>"5X=
M<S2?4'"=>'09;!ZCX*QI&()W]="[HK?4CIDM;L/%Z)&3;;NT+T+Q_AKSU*U#
MOWH N E*.A[7;P9E<RXZ9X0%MFHDYP?E!H(E*1$X=7S33(,ZAZ $C]_Z^NDS
MJGO_:QPRXM@)DB:IPRKCV<+Z%M"!P+H_%B&70Q@-/&=)?('!^9#WN"+5JFFO
M";DW?*G'6O=4#VX2&R 6@GK*E>,1&+C9R9O)?&4FL_K"3&:J,-N8RULRG\5F
MZ8F42H9M:CT-N[(S\WG@'^[N9/<R7<IFH8AT6*'W6Q#V6BU*LBZ?>>G=9%>7
M K'77$QTU'X1F2_'XMR']'LF/<%C_+S5"5+J?1L("%E\(\6AK_^[[SS;0[=4
M[R1-O__C#,8]I#FE:\,0EHC)R<X72.;O3,9> -DSF+WLO<DIFTZK5=L<*J M
MQF6G>?HD-R[?>+@;'E[I4+R=AN)I?-[(RHHZHM<L?B'HDI>$S&(V^9+PREX0
M6VM9GE^XL#Z<M:WB)N?'G\@=[@[/1@1+(5=TP$@+CYV#1.)]Z_=4T>25DP,4
M8=]??#2]I<->HI]6]],GZAZ[7^JLWVQ>S&JJ\YQF767U.5>B\1+)WI6B]^3:
M\'W>O=/Z>%'O?FG?\Q3OEC*VP[KCU:V*GL!WWX4NX\D-M\2/UFTC^N-@1CPZ
MQJT_O3V>7!+&:7J0X@(EH"%*'@/LL2$-^K@[B8 TI=,.6/ ;AS!&@Z-C-8P$
M(.=OML?^C)+J8LDLE<M/DE67S*)=>IK7@TKFL?WS\_/[ OH?J@OXOJGOKJG#
M/Y##E)]?@''/NZ.;I^,K6[7//.JZ];3TLZK ;(S1#^?IWIW8^VWFOK SB'F9
M)QW%XB$+R95)&E2PV6M67+SFN0F/[[P3^WPRIC>VWWH%XSMU>[\PZK"01X+\
MFWN,8/%-_Y,YD GCT3FFM]4;0\[ZZ1<\3'>IGR836^2_>Y*GYI-_$$K_(U*U
M_P-02P,$%     @ NTDP62%^LX1G @  4@<  !    !A;FDM,C R-# Y,38N
M>'-DS55;;]HP%'[G5WAYGG,#.A(5*HVJTB1V$6NUODV.<P)6$SNS':#_?K;!
M TK9AK2'\8)S_'WGG.]<DNN;35.C%4C%!!\'21@'"#@5)>.+<?!P?X='P<VD
MU[M^@_'C^_D,W0K:-< UFDH@&DJT9GJ)]!+0-R&?V(J@+S71E9 -QA-'FXKV
M6;+%4J,T3@<>YF]E/NH/*2%9BJMJ"'A0I!G.1N4 #RIZ50#TWPU'U=M%'I=%
MG-&RQ-F0I'B0I$-<7*4E)FE1I&D<#T>C@7.Z4;FB2V@(,M*XRC=J'"RU;O,H
M6J_7X;H?"KF(#".)'C_.OCIHL,/6C#\=H3>%K#V^']GK@BCP<,+9+[0YAU0T
MD1499\E5@(C6DA6=ACM3C5NH2%?K<=#Q'QVI6<6@-*6NP1;S"'!PK8E<@/Y$
M&E MH7 ^UJ2'D!7.FE9(C?@)XT!YDF59M+%2 K0MU$Q0HEW_SRIW>&R/.$EQ
M/PDWJ@RBOPI[[(AQI0FG<$EL\X0][U_DL&_C93EXWN4Y.&<*:+@0JZ@$9CO7
M?SV\.@>W!VP/QS$)YT([OK7L;&W+>"6V!F.RB><^^SE4?C-.QOV5$7%_.9%4
MBOH/\Q2U4K0@-0-UN"K.P5)"-0[,X&(_M-];":%)Q"-._!]WP%Z; *#,OCBY
ML[T>[T(_M\:%,FVH85NA_UA^38I+Y1L*U!?JML1[<X]8.0ZFPKSJ V1M#_,/
M)^\3%V2+\4Z\FQ(JQID;L]C]$H3W'P.,'.LZ>HE]X:534'[F$W=^V<L=>0?Y
M#9&2FG;UY;Q]6F=I.Z.OV6ZCHN.5VCX?K)TS;'=YTOL)4$L#!!0    ( +M)
M,%F'V7DK 0H  'U4   4    86YI+3(P,C0P.3$V7VQA8BYX;6S-G&]OV[H5
MQM_W4W#9FPVXK$F)HL2BS467VP[%<MN@27$O-@P&Q3^)4%L*9*5)OOTHV4ZL
M6+))RE:' (YC4^<Y#\V?R$/)>?OKPWP&?JARD17YNQ/\&IT E8M"9OGUNY-O
M5Q]A<O+KZ:M7;_\"X9__^'H.?BO$W5SE%3@K%:^4!/=9=0.J&P7^*,KOV0\.
M+F:\TD4YA_"T.>RLN'TLL^N;"@0H(.MFZW?+-TD8"<Y9 +6.%"1IP"!+)(%$
M"YHJ%<91HG^Y?H-DBIB0$K*(!Y#@(((I#23D09H& 4)1DI FZ"S+O[^I'U*^
M4,#8RQ?-G^].;JKJ]LUD<G]___HA+6>OB_)Z8HX,)^O6)ZOF#UOM[\.F-6:,
M39IWGYHNLJZ&)BR>_/G[^:6X47,.LWQ1\5S4 HOLS:)Y\;P0O&IZ?6]>H+=%
M_1=<-X/U2Q ',,2O'Q;RY/05 ,ON*(N9^JHTJ']_^_JI5Y)-ZA:37%W7G^V%
M*K-"7E:\K,YYJF8F^R9:]7BKWITLLOGM3*U?NRF5[@X[*\M6U#I+5F>):9WE
M7_O$)@/2/U"^U7:N!TBNL?OY4#GNZM//!TOWRIPAU/$3WI 9G/)R0'W(Y5AC
M]TEJ<.K'S_A0PZ*H^&R$8?$LLY'RK'[AW#Q;R=2!=IQ,&YW5J7LC5?50J5RJ
MY=FR%1ID\MV)>3:5*IO^46:5:7A6S.=W>;8\<R^FDB0A4B*!*E(8$HI2R%22
MP#BE">))9":R<%H]#>JIRN&WR[5^([)'X<3!6]7#:*D6Q5TIEK.;4:UG]F4B
MIRM-T!9].WG.SZ=79L?W.CNFS4*T L_JB;HH7UHIQ'XKSR-_8;PT/A9*O+XN
M?DS,L<9/$-9/8/VD&?#]$2=;G\3[<ITG+\6>3ENUF(C"K$)N*]CJ/UT6<TM#
M56'Y(2Z[SLB>@**4JC1KRPX+K<%TJ<2="?GXX4'<F$]/?>9S-<4)XP3C$#*-
M."0AX3 -S#E"\UA+0L*4),B6L"Z!(P.VE@1K35"+V@/6V2?[^1KJU TO1Y-.
M>.URXD579\#1X-IE9Y.MG>W\T<)!>I55,S5EB#$B$3+5E#1824P@"Y&&2"HD
MPB#4,7'&:AW\R$@U&J#0  =_2_\.UNKN3#UUACU//A;=6')UYP732QN#0'H*
M-CI$+VUT ;35QAV>NE"?7=P4N?I\-T]5.35XH #3U-39E!IXF,&((PE)K!-$
M%5$XP+;PO Q^9'@:.=#H@:6@/3=;_;"?FR'NW+AQ,.:$3)\#+V2V@HV&3)^-
M361ZV[@C<U7R>@?Q\G&>%F:$1%+'$:+0X"$,)6;&26*SFM.88$T8XHIK6UY:
MD8\]TRRUP%+,'I2V^_V4>'MRG%KL[#CAT9FZ%QOM2*.!T6E@DXKN!NY(?,@K
M,QU]RD51WA9E4RQ=5KQ29\5=7I6/9X54TR")0D9T E&@S:I,D!!RF@:0!9+B
MU/P$:6(+BH7>D?%99@!:*?P"FB1,KX%5(J#.Q)XMFV[<3]R!.\>-PT/TBQ.D
M#FZ]T+6)/QK0#F8W,7<YS!?^]U*:8;%HXGXI+\KB1V;L3,-0LX@F!.J F$6D
MC*-ZLX/ 1*=4I%32&%EO(NX2&@?WE?;&@%[KNT+>TUVV= _O!"^L/?Q[P+S;
MW "*>P*/C.]N>]O<[FGO#NQ%J>I]366BU%>[/RT6=ZJ\JB\4E%^T-K5/2",B
ME6)0FFK0K&FIA PK 5FL2$PB%+$XLH5VG]B1P37R4&SH@V4"8)D!:%*P9W=O
MS^WG]Y#]X<;PH*YPPMC6HQ?*>X./AK.MS4VDK8]QQWI]]\K3!=O?S EC&BAM
M6N( QM@\D"32D-4[HHI$6-#ZP?X:0Z?"D0%^NB=G*0J,*JAE[:'M[I?]I YV
MZX:GLU$G)'>:\>*P.^)H\.TTM$G<[H;NF)T5/U3Y/EU4)1>5Q3!JM3_>\&ED
MP'_60O\]S+#I3-YKN+0CC39,.@UL#H_N!KY5T(>Y*J^S_/J?97%?W9@S_2W/
M'Z<!94'<+* P,N=@'B.8*)S P*RG(LHQ#Y7U>FJ'SC@UT%H:++7!2MRU .KN
M*=OZ9[!_K_+'U;I'[;/3V(#2ISONR)7/3G/;A<_NYH/KGLUU.PL"1GFL((V"
M%!+,-4P-EU 2(E' DD@$TK/B^8FUSD&*G$'ES<\I;(Y>T1RIEOE_J&+<ZI?#
M5"Z7Q2P36650_]VLS<J,SZ:!X%I$FL((I:B^-0I#+L,4"AI'(N:$A]S^'HZM
M\$<&\5D0K!4=[N#8[HS]V VSZ(:;BSNW.SAZ3?C=P[$=;KR[.'JMM.[CZ&_E
M49?46X6EXLU5HGIAJ0FFD I$($$"0\:EP4<&.B1!&G-I?1?'9N C@W/6;#(;
M+<<+9RWO%B69IR/'BLS.C%L]UI&Y7SFV&6B\:JPC_58QUO7^P"M2%\6BXK-_
M9[?-X. \3+5$D:G"L(:$4@J3E')3BC%!TU!*FEB#T2\S\M6HI38PXEX7G#L[
MRK82&VK?JQ!S=NY_%:K3V/!K4.VP/^<*5*>UWNM/W:W]MZFOS*%3'3/-J IA
M',H$$B4$9"C@$+%(1)Q%6A/KNFLS\%B;TK66^TYT8]U^ ]K5D.>^\TXO7IO-
MFXD/VF-N HV^M;R9?M>.<NM]=Q#>FQBRCO-QQJ^G<8H%3R,S$[&:A"1.(<.I
MABJ6C#$:8!926Q):D8^,PI,6J,7L66B[WP^#MR<W&BSM..'0F;H7#^U(HP'1
M:6"3B.X&O@NW,Q.HY+-/N50/_U*/TY A,Q=@ K59M$&"S<(MB4TQPX)()'$L
M4(0#MS7;"X5QEFLK4="H B/KNDY[V2^V2[0!;KU69_9&/99E/68&K,A>1AQY
M,=9C:'L=UM?0%[./V6S]98>0$J;C$$.6,F268>:!1US!4"(DN9F (N%XE]YS
M\''@JO6<O_2QU0^V1/FY\X+)QI@'1ML.!A"T$6QD>+9M;'/3T6;@ED*]3?&E
MO"KN\VF$"8T5"2'5]=>E="HAUTC"B&H1"XE5@F*O_81GC9$W$YIMJZ($M;3G
M3L)&_SAN(_BY'K:'8&78?P-AV]+PW8.-F#]GZV#;5.^^04=37_RN^,,G:6;!
M3*^^D;\Z;:<J2;4@'%*,8K- 1 %,J(IAJ 45:8@BD3INZO4HC8.B$0=M=<^9
MK:^_;*$\0"]XH>G> 1YX[C$W -*^R".CNL?@-K#[#A@X:ZY^G6>YPE,J!$N)
M)!#A4$(2\?H[^CJ"D18!BC17H?T%JEZ5D6?.U1-0:X,ON>\^?*N?'.=/7_?#
M9E!KX_ZS:)>QX?-H*^K/F4F[C/7.I9V-?;'\JJZS^K;'O&K^\0H1H0R2)(2,
M85,#IJ& *8XXC"+)DRA684R5&Y%M@7%@?-9T_&<TG7UB2Y^_4R_P;$UZX-;M
M9 !I+P*.#%FWG6V^>MKUH;79XP;&[Z>OUJ]DR_]6>?KJ?U!+ P04    " "[
M23!9\1CF7J,&  #+,   %    &%N:2TR,#(T,#DQ-E]P<F4N>&ULU9IM;]LX
M$L??YU/X?&]O8CY*9-!DD<NVAV"SVZ#-8A?WQN##,!96E@)9:9)O?R,E;ILF
MW1,B U'?^($F-</__#PD1WKST^VZG'W"9E/4U>&<[[/Y#*M0QZ*Z/)S_?O$.
MS/RGH[V]-_\ ^//?'\YF/]?A>HU5.SMIT+489S=%NYJU*YS]43=_%9_<[+QT
M;:J;-<!1/^RDOKIKBLM5.Q-,J&VW[:_-@9$Z.&<%I*01E!<6K(D*5 J91Y2Y
M-NE?EP<L>F9#C&"U$Z"XT. S$<$)[X5@3!NC^HN61?770??BW09G-+UJTW\]
MG*_:]NI@L;BYN=F_]4VY7S>7"QHI%]O>\X?NMT_ZW\B^-[?6+OI?/W?=%,]U
MI,ORQ9^_GGT,*UP[**I-ZZK0&=@4!YN^\:P.KNU5_[]^S;[;H_L&VV[0-0$7
M(/G^[2;.C_9FLWLYFKK$#YAFW?OO'TX_FW15L1_J]:)K7YS4Q %YV(]H[Z[P
M<+XIUE<E;MM6#:;#.8V!+I+,\JPS\\_[<8LOUJX:W! B_>S.J.%A>&=DL&6\
M;;&*>#^)[87+.CSJ5'82UI]'ELYCV;<N(Q;+_JK'?M,V+K1+=%QZP2TP% &4
M$QR,8T12H+D8)K72X?%$.T\WY&JO^ ;#_F7]:4$7)N6%[#YT,LA>@B?F[N5X
MF=_;O]@%]5UJD9S.K02;H04E> 3/A0"FHG08>)9+,<KMKZT]]OKK,!XW858W
M$1O*$5MSK@F/0OJ4SH<>BRO7T(4@K(HR;D>GIE[O(E9MO0/E[L-"[LYG-.N$
M38/Q[#XJWYU</[.6,B?V/7<1\7-LBCJ^K>+/E%J7EG.,.5/ F*-T*+4!ZR/I
MX9WU'A73J'82^D=F!S$@IL_ R[5\91C>5FW1WGW RZ)3HFI_<VM<&A&RC( &
M;6G-4P$=+7S,@@NYC8DK'L0X%IZS.@@%.5T41BLY"1).:3O67-5-+_Q'TA]/
MZNNJ;>Y.ZHC+$+0+FK3)E26PK51@N%"0&Z$B&L^DX3L XV^=&,2)FCHGN]-Y
M$MB\*TK\[7KML5DF:Y,74H+228,RAM9$JR0$Y:*A8!N)?@>,?+$X" @]=2!>
MJ. DHG_A;D\C:56DXOZ4\3 1P26FR!E@'CBM?DJ 19I2I$V1,$&S+(S;!?^M
M^4%<9%/G8A?:3@*2XQ@I!)N'-SJI(5\*S9*WB&!D,'3,S@68X$@IS:,V(8JD
M< > /&-Z$!SYU.$8J^F4P#BAC^^;B_JF6E*R<PJ-(;9Y#DHEVC_3GAH<<9UR
M)X1(<G=8?#$\" KS@T#Q0CVGA$2_+WK?G#?UIZ(*M"TR3B;B%PR13&A'#C:/
M&;C,8>830XQQ=UQ\8WT0'/8'@6.,LE,BY+S>M*[\;W'5;YM162=-D,""\Z"2
MY^!91[S+HQ!&:Z;SW?'QR/:P8A;[0?!XN:RO#$>7](X;=+W?GJF8.9\@9CD#
M)?($CG=G<6-\RD,6,V2C</C:VC  )ES.?+%TKQSR[LY&>;ZJJ^WQB4FAD<D<
M1%0=KEJ#"\@!@PK!"I5+/FZ5^-;BL-!/N(HY2L)7#O]'#-<-H<N%ORC:$I?<
MTLDGD@BI+[EQY\#1;@<89W0V,BF8I$>%_UN+P\(_X<KE* E?.?P7C>ON'G^\
M6_NZ7"IM>.Y-!IF2="A6,8'-(NU[@W/2>BGI9#0J]H_,#0O\A$N1+Q=O(G_Z
MM[=AY:I+[&OM$C%DAI(68Y'6+$6G7Q>T *Z2"IIAKNVX:M-S5H<Q,.'JXV@I
M7QF%/\CY%JN3>KV^KAY*9)MEB-XIE>409*9!^4#[%^4U^"A5M(XSQ\;=J'C6
M[# 8)EQR'"_F:R>&NBQ"T5)2^Y4.N$WARF6>B9AY[<"BDJ2 U&"\]I3ED&A&
MEALU#H6G-H=Q,.'JXD@97QF"\P8[@K$*V#^?T3W:T[Q/Y,?26I^\Z&9!IU90
M& )8;PT0W2DEZTSNQCW@\GW;PZ"8<'5Q1[)."X[3S>8:FZ_G$C/.-3I+.:Y[
M],\0X]XS RPD-#9+2CBS2T2>># ,E E7&G<J\22JC6_7V%Q2-OQ/4]^T*YK<
ME:ONEDFZF.6T).:&4TK,G 1/O(,(3EOI ](N:@?EQF>-#WMP:O+UQO'"3H*/
M$Y*L<>4I(7[["][1 5J&&,EMHU@.BG$--N<1M-.**ZML%+L@XQNSPYB8< ER
MO)BO3,,QY;O8Y;QWI;M<"J]C[G,$&42W*GH)EOF,IB"%B3G7%L<5(A^9&Q;]
M"5<A7R[>SJ+^9O%$O#-J.-I[^*%[Z9Y]/]K['U!+ P04    " "[23!9>3K2
MGD<:  #'<@  'P   &%N:7!C;&]S:6YG+3(P,C0P.3$V>&5X>#DY,2YH=&WM
M76MSVT:6_;Z_HM=V'*D69"3J94L>5RFV[-&,8FLD.Z[]M-4$FF1'((!T Z28
M7S_WT0TT2%!^C!_2EE*)(Y% /^_CW'-OMY]-RFGZ_-E$R>3Y?SW[[UY/O,SC
M:JJR4L1&R5(EHK(Z&XL/B;)7HM=S3[W(BX71XTDI!EN#7?$A-U=Z)OG[4I>I
M>N[;>?8+__[L%^KDV3!/%L^?)7HF=/*W!UHEP^WA<#38&>X]W3U(AD_4:##:
MWY7#G4'R='M/_M_.W@-X%Y[GEVRY2-7?'DQUUILH',#A_D%_KRB/YCHI)X?;
M6UL_/: GGS\;Y5D)_1EXG7_D5NJVGC_3T[&0:0G#F,JQDOT_BO$#84V\] %W
MZ;H[V"ZNCZ;2C&$$P[PL\^DA=C]3IM2Q3'LRU>/LL%37I?O:C^S)7G']H-7]
MF@'6W_F>XSS-S>'#+?KG"+_IC>14IXO#GX^-ENG/D969[5EE](B_MOHO!6L!
MXZ)?YV[H\':J,^57;GN B_7J[84X_>VWDY>GQ^].Q,7)V<GQY<F:$76/UH^3
M)LWSCV'GE7GP=>:Q^[%Y;.,\CM^<BO.)-%,9JXKVPD;B-(O[(*S3(E6ELN(X
M_K/25I<ZST0^$L>IGBHCQ66L518K^T6S+F22@(;T4C4J#W?V8:RT#CI+8 T.
M>]M/BO(KK</ KP.U<ZA+6.NXM3*[G3O\^.&3P6#_R,_@QPWEJ+56VSM]6IO+
MTJAL7$Y49L6%-$J\U%9)JX158[)$THH4%$[94B1&@Z;AWHVJLH)GQR:?EY-(
M<,-"%H7)KT%[2Y4NQ*/MK3T!LTEQOW7&MLJHF<HJ)> C*>!I,<I!9L106KTJ
M />;_)4V^3A)K"CGN4@J(X>I$G$^!=V+H7O87ZM**T[/WO]^>O+F\</M@]TC
M(;-$_._[=Z?_<K_/=3D1%FR+'H%NP^1XYT61E[ %T$PDU'4!;Z$8@"W ]=@^
M.+*PO7DYR=,$!<"6!B1CK&,!XF9D089"@,Q)%*F\F)03F4YAN<:+>U'X9J(
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M[8HZ?Z2::%L7GGKO1_F:KU1PN@1[PX)2QMB@>.0971W'FLYK-:R[7D"$#(B
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M*[F6V.V5=T8ZI0-!=8 19/-P,"?7#EC#BU-M248W+D]>;+:(%DP@YE0K''/
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M?/RB#_[L_VTYZR_\%TG^0G^!Y;\!4$L! A0#%     @ NTDP62A ?2]K#@
M4VT  !               ( !     &%N:2TR,#(T,#DQ-BYH=&U02P$"% ,4
M    " "[23!9(7ZSA&<"  !2!P  $               @ &9#@  86YI+3(P
M,C0P.3$V+GAS9%!+ 0(4 Q0    ( +M),%F'V7DK 0H  'U4   4
M      "  2X1  !A;FDM,C R-# Y,39?;&%B+GAM;%!+ 0(4 Q0    ( +M)
M,%GQ&.9>HP8  ,LP   4              "  6$;  !A;FDM,C R-# Y,39?
M<')E+GAM;%!+ 0(4 Q0    ( +M),%EY.M*>1QH  ,=R   ?
M  "  38B  !A;FEP8VQO<VEN9RTR,#(T,#DQ-GAE>'@Y.3$N:'1M4$L%!@
0   %  4 30$  +H\      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ani-20240916_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ani-20240916.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2024-09-16</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001023024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-09-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ANI PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-31812</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">58-2301143</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">210 Main Street West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Baudette</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">56623</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">218</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">634-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">ANIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
